Poxel SA AI Stock Analysis
Want to see FR:POXEL full AI Analyst Report?
Poxel SA (POXEL) AI Stock Analysis
Poxel SA
(Paris:POXEL)
Poxel's score is heavily weighed down by its critical financial condition, including negative equity and high debt, which pose a going-concern risk. While technical indicators show some short-term strength, the overbought RSI and lack of earnings limit upside. The negative P/E further underscores the company's unprofitability. Overall, the stock carries very high risk.
Poxel SA (POXEL) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 11.01M
- Dividend Yield
- ―
- Average Volume (3M)
- 670.86K
- Price to Earnings (P/E)
- -0.4
- Beta (1Y)
- -0.08
- Revenue Growth
- ―
- EPS Growth
- ―
- Country
- France
- Employees
- 5
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Poxel SA Business Overview & Revenue Model
Company Description
Poxel S.A. is a clinical-stage biopharmaceutical firm dedicated to discovering innovative therapies for a range of conditions, including metabolic disorders, type 2 diabetes, and liver ailments. Its most advanced investigational drug, Imeglimin, is a...
How the Company Makes Money
Poxel makes money primarily through (1) product-related income from TWYMEEG (imeglimin) in Japan via its partnership with Sumitomo Pharma—this has historically included milestone payments and other collaboration-related receipts tied to development,...
Poxel SA Financial Statement Overview
Summary
Revenue growth and narrowing operating losses are positive, but negative equity, high debt, and negative operating cash flows indicate severe financial distress and going-concern risk. The overall financial position is precarious.
Income Statement
20Very NegativeBalance Sheet
5Very NegativeCash Flow
10Very Negative| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.66M | 6.64M | 1.98M | 674.00K | 13.40M | 6.81M |
| Gross Profit | 3.95M | 3.66M | 1,000 | 2,000 | 13.34M | 6.81M |
| EBITDA | -3.07M | -4.32M | -12.17M | -28.02M | -22.52M | -29.71M |
| Net Income | -13.66M | -18.30M | -35.09M | -31.40M | -23.76M | -31.86M |
Balance Sheet | ||||||
| Total Assets | 5.00M | 14.93M | 4.82M | 34.71M | 54.89M | 65.08M |
| Cash, Cash Equivalents and Short-Term Investments | 2.06M | 3.66M | 2.34M | 13.06M | 32.29M | 40.20M |
| Total Debt | 60.99M | 69.71M | 47.03M | 43.44M | 35.14M | 23.62M |
| Total Liabilities | 66.41M | 73.87M | 53.90M | 52.95M | 46.68M | 38.20M |
| Stockholders Equity | -61.40M | -58.94M | -49.10M | -18.24M | 8.21M | 27.07M |
Cash Flow | ||||||
| Free Cash Flow | 7.54M | 0 | 3.05M | -21.84M | -16.94M | -26.03M |
| Operating Cash Flow | -7.21M | -17.61M | -13.98M | -21.81M | -16.89M | -25.75M |
| Investing Cash Flow | 28.00K | 92.00K | 41.00K | -5,000 | -42.00K | 52.00K |
| Financing Cash Flow | 6.43M | 18.82M | 3.23M | 2.58M | 9.03M | 28.71M |
Poxel SA Peers Comparison
Overall Rating
FR:MEDCL61Neutral
FR:IVA50Neutral
FR:POXEL46Neutral
FR:GNFT45Neutral
FR:ALVAL44Neutral
FR:ALGAE37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 61Neutral | EUR 980.50M | -29.96 | ― | ― | -23.21% | -50.69% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | EUR 756.76M | -5.97 | -1625.48% | ― | -99.64% | 68.67% | |
| 46Neutral | EUR 7.36M | -0.36 | 33.88% | ― | ― | ― | |
| 45Neutral | EUR 525.95M | -5.17 | 279.22% | ― | 27.70% | -162.89% | |
| 44Neutral | EUR 20.61M | -1.97 | -84.11% | ― | 183.47% | 57.15% | |
| 37Underperform | EUR 47.33M | -4.54 | -32.62% | ― | 3.22% | 24.05% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:POXEL | Poxel SA | 0.14 | -0.10 | -41.20% | |
| FR:GNFT | Genfit SA | 10.54 | 6.73 | 176.79% | |
| FR:IVA | Inventiva SA | 3.17 | -0.33 | -9.57% | |
| FR:ALVAL | Valbiotis SA | 0.58 | -0.12 | -16.79% | |
| FR:ALGAE | Fermentalg SA | 0.40 | -0.05 | -11.83% | |
| FR:MEDCL | MedinCell SA | 27.26 | -0.86 | -3.06% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Feb 03, 2026
